In Vitro Safety "Clinical Trial" of the Cardiac Liability of Hydroxychloroquine and Azithromycin as COVID19 Polytherapy
B. Charrez, V. Charwat, B. Siemons, H. Finsberg, A. Edwards, E. Miller, K. Healy
This paper uses a cardiac microphysiological system to assess the cardiotoxicity of hydroxychloroquine and azithromycin polytherapy, finding increased QT interval and reduced arrhythmias compared to monotherapy.
bioRxiv · Dec 21, 2020 · PreprintBioengineering